News
also known as TIM-3, in combination with AstraZeneca's anti-PD-L1 mAb IMFINZI (durvalumab) for the treatment of advanced hepatocellular carcinoma (HCC）in China. BioCity will lead the trial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback